2019
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ippolito D, Querques G, Pecorelli A, Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal Of Computer Assisted Tomography 2019, Publish Ahead of Print: &na;. PMID: 30407241, DOI: 10.1097/rct.0000000000000807.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaProgressive diseasePartial responseDynamic contrast-enhanced perfusionPerfusion CT valuesHepatic perfusion indexResponse Evaluation CriteriaMultifocal hepatocellular carcinomaIntravenous bolus injectionBlood flow changesContrast-enhanced perfusionRow Computed TomographyPerfusion CT techniquesStandard of referenceNonprogressor groupProgressor groupSorafenib administrationCirrhotic patientsArterial perfusionHepatic perfusionPD patientsTumor responsePerfusion indexTherapeutic response
2018
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions
Ippolito D, Querques G, Okolicsanyi S, Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaAnti-angiogenic therapyPerfusion CT imagingHepatocellular carcinomaPerfusion parametersProgressor groupSurvival rateNon-progressor groupOverall survival rateKaplan-Meier analysisAssessment of responseAntiangiogenetic treatmentCirrhotic patientsSorafenib administrationPrognostic indicatorTumor responseTarget lesionsHCC lesionsIndividualized treatmentTumor neoangiogenesisPatientsOverall populationHigher survival rateCT imagingSurvival prediction
2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2010
Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching
Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F, Investigators O. Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. Digestive And Liver Disease 2010, 43: 155-164. PMID: 21185796, DOI: 10.1016/j.dld.2010.11.002.Peer-Reviewed Original ResearchConceptsDonor risk indexObservational cohort studyHepatocellular carcinomaLiver transplantationCohort studyDonor ageVirus infectionDeceased heart-beating donorsHepatitis B core antibodyMedian cold ischaemia timeMedian donor risk indexProspective observational cohort studyEnd-stage liver diseaseHepatitis B virus infectionHepatitis C virus infectionLiver MatchDonor populationItalian transplant centersOlder donor ageViral-related cirrhosisB core antibodyC virus infectionStage liver diseaseB virus infectionHigh-risk donorsGenetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C
Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal Of Hepatology 2010, 52: 712-717. PMID: 20347497, DOI: 10.1016/j.jhep.2009.11.029.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCholangitis, SclerosingChromosome MappingChromosomes, Human, Pair 6EuropeFemaleGene FrequencyHLA-B AntigensHLA-C AntigensHLA-DR AntigensHLA-DRB1 ChainsHumansInflammatory Bowel DiseasesItalyLiver CirrhosisMaleMicrosatellite RepeatsMiddle AgedReference ValuesRisk AssessmentYoung AdultConceptsPrimary sclerosing cholangitisSclerosing cholangitisHLA-DRB1Risk of PSCTNF-alpha -308GNatural killer cellsP-valueChi-square testHLA-C2PSC patientsKiller cellsTumor necrosisPSC pathogenesisT lymphocytesSignificant associationAbstractTextMICA locusHLA complexHLADRB1CholangitisUncorrected p-valueKIRFurther studiesAIMS
2007
Inheritance of hyperbilirubinemia: Evidence for a major autosomal recessive gene
Clementi M, Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, Tenconi R, Okolicsanyi L. Inheritance of hyperbilirubinemia: Evidence for a major autosomal recessive gene. Digestive And Liver Disease 2007, 39: 351-355. PMID: 17347060, DOI: 10.1016/j.dld.2006.12.019.Peer-Reviewed Original Research
1990
Effect of age on single- and multiple-dose pharmacokinetics of erythromycin
Miglioli P, Pivetta P, Strazzabosco M, Orlando R, Okolicsanyi L, Palatini P. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. European Journal Of Clinical Pharmacology 1990, 39: 161-164. PMID: 2253666, DOI: 10.1007/bf00280051.Peer-Reviewed Original ResearchConceptsElderly subjectsEffect of ageSerum concentrationsSerum concentration-time curveMultiple-dose pharmacokineticsApparent oral clearanceMultiple-dose regimenPeak serum concentrationHealthy elderly subjectsConcentration-time curvePharmacokinetics of erythromycinNormal elderly subjectsYoung healthy adultsMean eliminationTwo-fold accumulationFirst doseOral clearanceOral dosesMultiple dosesMultiple dosingPresystemic clearanceTime-dependent reductionErythromycin stearateAge-related differencesElderly group